<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-030565
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20051003
<FILING-DATE>20051003
<DATE-OF-FILING-DATE-CHANGE>20051003
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>051115749
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v026620_6-k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of October 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 15pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English) </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="3">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSIVIDA
                LIMITED</strong></font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:&#160;October
                3, 2005</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%">
              </td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td>
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
                  Finlay</font></div>
                <div><font size="2"><em>Chief Financial Officer and Company
                  Secretary</em></font></div>
              </td>
            </tr>

        </table>
      </div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="3">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td align="left" valign="top" width="15%">&#160;</td>
              <td align="left" valign="top" width="62%">&#160;</td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="62%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press
                  release, dated October 3, 2005, announcing merger agreement among
                  pSivida
                  Limited, pSivida Inc., and Control Delivery Systems
                  Inc.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="3">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v026620_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
        99.1</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right">&#160;<img src="logo.jpg" alt=""></div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="50%">&#160;</td>
              <td width="50%">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="50%"><strong><font size="2">NASDAQ/MEDIA
                RELEASE</font></strong></td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>3
                  October 2005</strong></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        to acquire </strong></font><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Control
        Delivery Systems</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div>
          <hr style="COLOR: #000000" align="left" noshade size="1" width="100%">
        </div><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><strong>&#183;&#160;&#160;</strong></font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Creates
                  one of the world&#8217;s first bio-nanotech companies with product
                  revenues</strong></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><strong>&#183;&#160;&#160;</strong></font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commercialized
                  products include Vitrasert</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol"><strong>&#210;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                  for CMV retinitis and the recently launched Retisert</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol"><strong>&#212;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                  for uveitis</strong></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><strong>&#183;&#160;&#160;</strong></font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Diversified
                  product pipeline includes Medidur</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol"><strong>&#212;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                  for diabetic macular edema in Phase III
                  trials</strong></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><strong>&#183;&#160;&#160;</strong></font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Existing</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                  licensing / development agreements with Bausch &amp;
                  Lomb</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                  and Alimera Sciences</strong></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><strong>&#183;&#160;&#160;</strong></font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Extensive
                  patent portfolio</strong></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><strong>&#183;&#160;&#160;</strong></font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Operating
                  base in Boston, MA biotech</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                  hub for further expansion into U.S. market
                  </strong></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><strong>&#183;&#160;&#160;</strong></font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Expected
                  to close in Q4 2005</strong></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div>
          <hr style="COLOR: #000000" align="left" noshade size="1" width="100%">
        </div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
        bio-nanotech company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(ASX:PSD,
        NASDAQ:PSDV, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        is
        pleased to announce that it has entered into a definitive merger agreement
        to
        acquire Control Delivery Systems, Inc. (&#8220;CDS&#8221;), a private U.S. drug delivery
        company located in the Boston, Massachusetts area. The acquisition is expected
        to close in the fourth quarter of 2005 and is subject to Australian regulatory
        and pSivida shareholder approvals, as well as other customary closing
        conditions.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Key
        Terms</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#167;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Funded
                  through the issue of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">approximately
                  16 million pSivida American Depositary Shares (&#8220;ADSs&#8221;) to CDS
                  stockholders, representing approximately 40% ownership of the combined
                  company. </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#167;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based
                  on a price of US$6.50 (AU$8.66) per pSivida ADS, the transaction
                  would
                  represent a purchase price of approximately US$104 million (AU$139
                  million) and an implied market capitalization of approximately
                  US$250
                  million (AU$333 million) for the combined company.
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#167;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CDS
                  shareholders will be subject to lock-up periods </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ranging
                  from 6 to 9 months, while pSivida Executive Directors have agreed
                  to a
                  voluntary 6 month lock-up period.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Key
        Benefits</strong></font></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#167;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenue
                  generated from existing product sales with near-term increased
                  revenues
                  from newly marketed products.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#167;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Robust
                  product development pipeline with several product candidates in
                  late stage
                  clinical development.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#167;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Leverages
                  the synergistic technology platforms of both
                  companies.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#167;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Short
                  to medium-term: the combined company plans to capitalize on its
                  BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  (pSivida) and AEON</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  (CDS) drug delivery technologies to develop a series of products
                  focusing
                  on ophthalmology and oncology. </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#167;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Longer-term:
                  the combined company </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">expects
                  to develop novel drug delivery products in a range of therapeutic
                  areas.
                  Furthermore, the combined company will continue to utilize its
                  platform
                  technologies, both on its own and through partnerships, to develop
                  innovative healthcare products in the non-core areas of diagnostics,
                  orthopedics, tissue repair, and food technology.
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        acquisition, an integral part of pSivida&#8217;s on-going U.S. growth strategy, will
        bring additional development and regulatory expertise to pSivida&#8217;s management
        team. This combination also provides pSivida with an operating base in the
        Boston biotech hub, enhancing its overall visibility as well as access to
        the
        U.S. scientific and investment communities.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="3">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Combined
        company&#8217;s marketed products and lead product candidates:</strong></font></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td align="left" valign="top" width="9%">&#160;</td>
              <td align="left" valign="top" width="19%">&#160;</td>
              <td align="left" valign="top" width="55%">&#160;</td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="9%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Marketed</font></div>
              </td>
              <td align="left" valign="top" width="19%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Retisert</strong></font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>for
                  Uveitis</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                  (CDS)</strong></font></div>
              </td>
              <td align="left" valign="top" width="55%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
                  intravitreal drug implant marketed by Bausch &amp; Lomb</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
                  approved by the FDA</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  for the treatment of chronic non-infectious</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  uveitis affecting the posterior segment of the eye,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  a
                  sight threatening inflammatory disease </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">that
                  is the third largest cause of blindness in the U.S.</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Two
                  long-term, multi-center clinical trials of Retisert&#8482; for DME are also
                  ongoin</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">g.</font></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td align="left" valign="top" width="9%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Marketed</font></div>
              </td>
              <td align="left" valign="top" width="19%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Vitrasert&#174;
                  for CMV Retinitis </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(CDS)</strong></font></div>
              </td>
              <td align="left" valign="top" width="55%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
                  </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">intravitreal
                  drug implant </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">marketed
                  by Bausch &amp; Lomb</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
                  approved by the FDA for the treatment of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AIDS-related
                  Cytomegalovirus (CMV) Retinitis</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
                  a
                  blinding condition in immune compromised patients.</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="9%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase
                  III</font></div>
              </td>
              <td align="left" valign="top" width="19%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Medidur</strong></font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup><strong>&#160;</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>for
                  DME (CDS)</strong></font></div>
              </td>
              <td align="left" valign="top" width="55%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
                  injectable, non-erodible intravitreal device for DME, designed
                  to be
                  administered in an office procedure. DME is a major cause of vision
                  loss
                  in working age patients. </font></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td align="left" valign="top" width="9%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase
                  IIb</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br>(2</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>nd</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  half 2005)</font></div>
              </td>
              <td align="left" valign="top" width="19%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BrachySil</strong></font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup><strong>TM
                  </strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>for
                  non-operable liver cancer (pSivida)</strong></font></div>
              </td>
              <td align="left" valign="top" width="55%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
                  non-degradable, radioactive 32-phosphorus form of BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  for the treatment of non-operable liver cancer tumors.</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="top" width="9%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase
                  IIa</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(2</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>nd</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  half 2005)</font></div>
              </td>
              <td align="left" valign="top" width="19%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BrachySil</strong></font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup><strong>TM
                  </strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>for
                  non-operable pancreatic cancer (pSivida)</strong></font></div>
              </td>
              <td align="left" valign="top" width="55%" style="BORDER-BOTTOM: medium none">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
                  non-degradable, radioactive 32-phosphorus form of BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  for the treatment of non-operable pancreatic cancer
                  tumors.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gavin
        Rezos, Managing Director of pSivida, said, &#8220;This acquisition is an excellent
        opportunity for pSivida to capitalize on the combination of complementary
        technologies and skills. The diversified product portfolio and development
        capabilities of the combined company present value creating opportunities,
        reducing our overall risk profile</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        whilst
        generating significant current and near term revenues.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Paul
        Ashton, President and CEO of CDS, said, &#8220;By bringing together our existing
        platforms and expertise, the combination of CDS and pSivida will potentially
        create a leading global bio-nanotech company developing next generation products
        and technologies in the areas of ophthalmology, oncology, and drug delivery
        generally. From our perspective, this acquisition has significant benefits
        to
        our shareholders in terms of future value enhancing prospects. We are
        particularly excited about the potential to integrate BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#160;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
        our
        drug delivery technology platform to create next generation
        treatments</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        for a
        broad range of diseases and conditions.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CDS
        at a glance</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CDS
                  is a private company based near Boston, MA. It was founded in 1992
                  and is
                  engaged in the design, research and development</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  of
                  innovative, sustained-release drug delivery products based on its
                  proprietary delivery technologies:</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 36pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 27pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AEON&#8482;
                  system: a linear drug delivery implantable system</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
                  with controlled delivery over months to years, non-erodible / erodible,
                  and currently employed in two marketed products; Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM
                  </sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">and
                  Vitrasert&#174;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 36pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 27pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CODRUG&#8482;
                  system: a non-linear drug delivery system, with controlled delivery
                  over
                  hours to weeks,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  polymer-free, bio-erodible, and in</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  early clinical studies</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 36pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CDS&#8216;
                  portfolio of products and product candidates includes</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  two approved and marketed products, one Phase III product, and
                  other
                  early-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  stage product candidates</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CDS
                  has strategic collaborations with Bausch &amp; Lomb</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  and Alimera Sciences</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CDS
                  has 41 patent families, 38 issued patents, including 12 issued
                  U.S.
                  patents, and 210 patent applications pending
                  worldwide</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CDS
                  has an experienced management team, state-of-the-art lab facilities,
                  a
                  lean infrastructure, and low overhead
                  expenses</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt">&#160;</td>
              <td>&#160;</td>
            </tr>

        </table>
      </div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 18pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CDS
                  develops sustained-release drug delivery products for severe and
                  chronic
                  eye diseases. Bausch &amp; Lomb recently launched CDS&#8217; Retisert&#8482; ocular
                  implant for uveitis. With partner Chiron Corporation, CDS previously
                  developed and commercialized Vitrasert&#174; for CMV retinitis, now marketed by
                  Bausch &amp; Lomb. CDS&#8217; pipeline also includes Medidur&#8482;, an injectable
                  long-term sustained release product in Phase III trials for treatment
                  of
                  DME.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="3">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CDS
        larger shareholders include:</font></div>
      <div align="left">
        <table border="0" cellpadding="0" cellspacing="0" width="60%">

            <tr bgcolor="#ffffff">
              <td align="left" valign="bottom" width="40%">&#160;</td>
              <td width="2%">&#160;</td>
              <td align="left" valign="bottom" width="1%">&#160;</td>
              <td align="right" valign="bottom" width="8%">&#160;</td>
              <td align="left" valign="bottom" width="1%">&#160;</td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bausch
                  &amp; Lomb Incorporated</font></div>
              </td>
              <td width="2%" style="BORDER-BOTTOM: #ccffcc">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ccffcc">&#160;</td>
              <td align="right" valign="bottom" width="8%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">18.52</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dr
                  Paul Ashton</font></div>
              </td>
              <td width="2%" style="BORDER-BOTTOM: #ffffff">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ffffff">&#160;</td>
              <td align="right" valign="bottom" width="8%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16.32</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">St
                  James &amp; Associates LLC</font></div>
              </td>
              <td width="2%" style="BORDER-BOTTOM: #ccffcc">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ccffcc">&#160;</td>
              <td align="right" valign="bottom" width="8%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.89</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Essex
                  Woodlands Funds</font></div>
              </td>
              <td width="2%" style="BORDER-BOTTOM: #ffffff">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ffffff">&#160;</td>
              <td align="right" valign="bottom" width="8%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.13</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">T.
                  Rowe Price Funds</font></div>
              </td>
              <td width="2%" style="BORDER-BOTTOM: #ccffcc">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ccffcc">&#160;</td>
              <td align="right" valign="bottom" width="8%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.28</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Morgan
                  Stanley Funds</font></div>
              </td>
              <td width="2%" style="BORDER-BOTTOM: #ffffff">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ffffff">&#160;</td>
              <td align="right" valign="bottom" width="8%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.47</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brookside
                  Capital Partners LP</font></div>
              </td>
              <td width="2%" style="BORDER-BOTTOM: #ccffcc">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ccffcc">&#160;</td>
              <td align="right" valign="bottom" width="8%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.85</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Essex
                  Private Placement Funds</font></div>
              </td>
              <td width="2%" style="BORDER-BOTTOM: #ffffff">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ffffff">&#160;</td>
              <td align="right" valign="bottom" width="8%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.14</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#ccffcc">
              <td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SMALLCAP
                  World Fund, Inc</font></div>
              </td>
              <td width="2%" style="BORDER-BOTTOM: #ccffcc">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ccffcc">&#160;</td>
              <td align="right" valign="bottom" width="8%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.14</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ccffcc">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td align="left" valign="bottom" width="40%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Anvil
                  Investment Associates LP</font></div>
              </td>
              <td width="2%" style="BORDER-BOTTOM: #ffffff">&#160;</td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ffffff">&#160;</td>
              <td align="right" valign="bottom" width="8%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.78</font></div>
              </td>
              <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: #ffffff">
                <div style="DISPLAY: block; MARGIN-LEFT: 0px; TEXT-INDENT: 0px; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">%</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Retisert</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
        (CDS)</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        is the
        world's first intravitreal drug implant for the treatment of chronic
        non-infectious uveitis</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        affecting the posterior segment of the eye, a sight-threatening inflammatory
        disease that primarily afflicts people between the ages 20 and 50. This
        condition affects an estimated 175,000 people in the U.S. and an estimated
        800,000 people worldwide. The implant is designed to deliver sustained levels
        of
        drug for approximately 2&#189; years directly to the back of the eye.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        The
        product is marketed by Bausch &amp; Lomb and was launched in
        mid-2005.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Uveitis
        is an autoimmune condition, which manifests itself as an inflammation inside
        the
        eye, that can lead to sudden or gradual vision loss.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Medidur</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM
        </strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(CDS)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        is an
        injectable non-erodible intravitreal device for the treatment of DME. It
        is
        administered</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        in an
        office procedure as opposed to a surgical procedure. The implant releases
        a
        constant amount of drug to the back of the eye and is designed to have a
        duration of between 18 months and three years. The product is being developed
        in
        collaboration with Alimera Sciences and is currently in Phase III
        trials.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DME
        is
        the leading cause of vision loss for Americans under the age of 65. Retinal
        blood vessels in diabetic&#8217;s eyes deteriorate and leak, causing the retina to
        swell. A minority of cases receive</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        long-term benefit from laser treatment. There are approximately 500,000
        treatable cases in the U.S. alone. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BioSilicon</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>&#160;</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(pSivida)
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As
        a new
        and exciting biocompatible material, BioSilicon&#8482; offers multiple potential
        applications across the high growth healthcare sector, including controlled
        release drug delivery, targeted cancer therapies (including brachytherapy
        (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BrachySil</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>TM</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
        and
        localized chemotherapy), tissue engineering, wound healing orthopedics, food,
        and diagnostics. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        owns the intellectual property rights to BioSilicon&#8482; for use in or on humans and
        animals. The IP portfolio consists of 29 patent families, 34 granted patents
        and
        over 80 patent applications. The core patent, which recognises BioSilicon&#8482; as a
        biomaterial was granted in the UK in 2000 and in the US in 2001. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>AION
        Diagnostics</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        Australia, pSivida has incorporated AION Diagnostics to commercialize a
        BioSilicon&#8482; based product portfolio for in the biosensor and healthcare
        diagnostic sectors. pSivida has seed funded AION and has licensed diagnostic
        and
        sensor applications of the BioSilicon&#8482; platform technology to AION. Development
        of potential diagnostic applications will capitalize on the use of the
        biodegradable, optical, semi-conductor and micro machining properties of
        BioSilicon&#8482; to develop novel sensors, diagnostic and continual monitoring
        devices.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Food
        Industry</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is also engaged in the development and commercialization of nutraceuticals
        and
        food technology products utilizing BioSilicon&#8482; technology. This is a non-core
        area and is expected to be spun out to a new subsidiary company in the next
        year.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="3">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Advisors
        to the Transaction</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BIO-IB
        LLC, a New York based healthcare investment banking boutique, acted as financial
        advisor and Curtis, Mallet-Prevost, Colt &amp; Mosle LLP acted as legal advisor
        to pSivida. UBS Investment Bank acted as financial advisor and Ropes &amp; Gray
        LLP acted as legal advisor to CDS.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vitrasert&#174;
        and Retisert&#8482; are trademarks of Bausch &amp; Lomb incorporated</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-ENDS-</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Released
        by:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                  Limited</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                  Leedman</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                  Relations</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  Limited</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  + 61 8 9226 5099</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
              </td>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                  Public Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverley
                  Jedynak</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                  E. Janis &amp; Company, Inc</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +1 (312) 9 1100 ext. 12</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
              </td>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                  &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                  Swallow, PhD / Helena Podd</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                  Dewe Rogerson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +44 (0)20 7638 9571</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="26%">&#160;</td>
              <td align="left" valign="top" width="26%">&#160;</td>
              <td align="left" valign="top" width="26%">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
        TO EDITORS:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is a global bio-nanotech company committed to the biomedical sector and the
        development of products in healthcare. The company&#8217;s focus is the development
        and commercialisation of a modified form of silicon (porosified or
        nano-structured silicon) known as BioSilicon&#8482;. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        owns the intellectual property pertaining to BioSilicon&#8482; for use in or on humans
        and animals. The IP portfolio consists of 29 patent families, 34 granted
        patents
        and over 80 patent applications. The core patent, which recognises BioSilicon&#8482;
        as a biomaterial was granted in the UK in 2000 and in the US in 2001.
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
        the
        Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
        and in
        Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
        PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
        pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
        Market Service (IMS) under the ticker symbol </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        pSivida
        is a founding member of the NASDAQ Health Care Index and the Merrill Lynch
        Nanotechnology Index.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
        largest science and technology company in Europe. QinetiQ is the former UK
        government Defence Evaluation Research Agency and was instrumental in
        discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
        having access to its cutting edge research and development facilities. For
        more
        information on QinetiQ visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.qinetiq.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        more
        information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        announcement does not constitute an offer of any securities for sale or the
        solicitation of an offer to buy any securities. Any securities offered may
        not
        be or have not been registered under the US Securities Act of 1933, as amended,
        and may not be offered or sold in the United States absent registration or
        an
        applicable exemption from registration requirements."</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        document contains forward-looking statements that involve risks and
        uncertainties. Although we believe that the expectations reflected in such
        forward-looking statements are reasonable at this time, we can give no assurance
        that such expectations will prove to be correct. Given these uncertainties,
        readers are cautioned not to place undue reliance on such forward-looking
        statements. Actual results could differ materially from those anticipated
        in
        these forward-looking statements due to many important factors including:
        our
        failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        due to
        regulatory, scientific or other issues, our inability to negotiate and
        consummate the proposed acquisition, our inability to successfully integrate
        CDS&#8217;s operations and employees; the failure of CDS&#8217;s products</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        to
        achieve expected revenues and the combined entity&#8217;s inability to develop
        existing or proposed products. Other reasons are contained in cautionary
        statements in the Registration Statement on Form 20-F filed with the U.S.
        Securities and Exchange Commission, including, without limitation, under
        Item
        3.D, "Risk Factors" therein. We do not undertake to update any oral or written
        forward-looking statements that may be made by or on behalf of
        pSivida.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="3">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0U!17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-3HQ,#HP
M,R`P-CHU-3HQ-0```````Z`!``,````!``$``*`"``0````!````I:`#``0`
M```!````-``````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```P+````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,@"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]52257-LRZ@+*-A:![FN!+B?S=NTIF3(
M,<#,@D1WX=2H"VTDJE&8_*Q#;0P>J#M-;S`#@?<"YJI.ZUE-N-)H9Z@=LC<>
M9V^"KY>?Y?'&$I2/#E%PD(RE&5]-/TOZJX0)OP='-SL/`QGY6;<S'QZQ+[+"
M&@?^9?NM6.W/Z]UG7IE8Z7@'Z.=EL+K[!^_BX#BST6:?SN;_`.PB+?TS$;D'
MK74V&_)IC[-4]YLJJ.@:[%I<UE=5SW?2NV>K_P`(C_;\YF.[)?2VPD;:<9DA
M[K#_`#;/4=[-G[]OYBE^\0]R.,<1G,<7#P_)'O/B^588RHDFHCMN6A@.ZEC?
M6AW33GV]0Q1A_:,GUVU37:ZSTZ/3?C58^SUF-M_0N_<71+.Z-TMV!5;;DO%W
M4,Q_K9MXF'/C:RJO=[OL^/7^AQV?N+14R(`UKUU4DDJF;U&C#@/ESW:AC>8_
M>=^ZF9<L,4#/)(0@-Y%>`3H&VDL[%ZUCWV"MS34YQAI,$3^[*LYV39C4>I77
MZKMP&T3W_JRHH<Y@GBEFA,3A#YC$&Q_@_,KA(-$-A)"QK778]=KV['/$EOA]
MZ*IXR$HB0VD!(>4D*269]8>J9/2NEV9N+CG+M8Y@%(W20YP:3^C:]WM4^@]1
MR.I])Q\[)H.+=<"7T&9;#G,_PC6/_-W?116\0XN'K5N@DJ_4,QF!@9.:]I>S
M&J?<YC8DAC386MG^JJ?U=Z_1U_!=FT5/H8RUU6RR)EH:[=["[]])/$+$;U/1
MU$DDDDO_T/54#,$XS])X/CP?ZEW_`)Z1UE?6#K'[.QZZ**OM?4<YQIPL28]1
M\>]]A_,QJ&?I,BW\QB;DCQPE']X&/VJL#4]&B[,S\+'R6=.QCDYU]S:L>LR*
MV.<UQ^TY;MM?I8M6WW_H_P!)_,UJ#PX=0`>9>+6[R-`7;F[RT?N[EH#IW4*G
MLOQW55V;`+&-G;/YS?=/JMW?0?\`HWK-L];[:=VWU_5UCZ._=_U.Y<YSON8\
M&##DQRB<68GB^:&2,I<8X)?X3+'61D#N-NSK=;UIHK&I?:-/&`[R=_U*LX+8
MHDB"7$C2/_16/_Y[53]GY]][;<NRLAH(:V"X"?W6^SW?RUI,8RM@8P0UN@"U
MN6ADGS.3F)0..$@(0C/^</#^EPK21P@;LEQ74?K1]8*?K??T;`KJR6[0W&H?
M#/>ZEE_J77?2]*G]):]C?>_^;8NU7GY__*P/]?\`M&M`=?)K9R1[=$CBR1B:
M[%L]#^LOUAH^LYZ#UXU6.LEK7U@-#';/7J=6Y@;ZE-M?^D9ZN_\`MK;ZL'4]
M1KOL9OK(:0#P=OTF+F.J:_XS\6.QIG_MMZ[B_+P7W?8;?>]YVEA:8!(W-]Q5
M/XEAAEPQB<D<4N*)QRE\IRCY8\/Z7$NY64KF#<N&1CKOPH33T[JCFW!QW,'N
M:#M=Y>I^=[?Y*-U/(MQL7U*B`[<!KKH5E=0Q?V=?7=CO(!DL!Y$<MG\YCE?Z
MR[=T\.XW.88^*HC/(8>=$H##S6*/%DGBVR>G]7DB6Q6L=;B>[G?63JO5<+ZL
MCJF"]C;ZW5NN+F[@6./HNAO]:QCU5S?K5E5?4BGK518,V\,K!+9;ZN_TKG;/
M^MVN6P[";U#ZO/P7<9..ZN3V+FEK7?V7+RNO*NSNCX'U>&[UCG.);V'J`4M;
M_8M?>M;EB98,1.I,($D_W6ES,Y0F:.DXF,1_7O\`1>[RNN];Q?J/5UBQ[/VA
M:*WSL&T-L?[&^G_Q+E>Z5U^\_4]O7<Z++F466O#1L#BQSVL8WZ6S?M:Q5_KY
M4RGZHV4UB&5&EC1X!KV-:LVG_P#)6?\`PN[_`,_.4O3ZJ,I1R2%D\.+B_P`(
M=6A3USZX]4Z'U/.NKIR>F.JNIM8V*GU@L=ZEV-H?5KQFO]_K6;[/\&M7_%WD
M58GU5R\FXQ51?=8\C4[6UU.='W('U>@_XN.HQR*LR?\`->B_XO\`,HP/JEF9
MN02*<>^VRPC4PUE1]O\`*2/7S68[X\<C(FX2E<M7.9]:/KQU>C)ZITNIE'3\
M7<7,VL)#6CU'-F_WW6LJ]UOI^G_P:ZKZH?6"SK_2CDWL;7D4V&FX,G:2`VQM
MC-VYS6OKL:N;_:/UJ^M.#F9M5K>D]&I99[&#=;;L:7NK]0^[_@[7L]"O\S]/
M[U<_Q6Z](S#Q^M?^BJ4CLG%*7N@<4I1E$FY;&OW(_HO_T?4<B^G&Q[,F]P93
M2QUECSP&M&][O[+0L+ZLXMV=;9]9^H,+<K/;MPZG?X##G=14/^%R/Z1D.1?K
M;G].QNGC&ZKOKZ=U$OQ<C)9/Z+<QSJW':'_3<S9]%`/UVZ19&/T:J_J][1`J
MQ*G;&]F>K?8*Z*:_Y:+'*4>+4CT]/%Z-<D_)^U=3L&`6VM;D;7Y9DT,=N_FV
M$?TO)_X"GV5_X>U6V]*ZYUH[^OVC#P7<=)Q'GW`_FY^<W99=SMLHQO2H_P",
M6B>AXD,:USZV5C;577M8QC1]%E5;&;:VJCS_`"QS1Q\,/=ECEQQB9>W"_P"O
M^G+^Y%DA(F_T`>OZ7_H+>J86,#7.+W<N<>Y^'YJFAT4FEFPV/MUG=89/PX"(
MKD22`9#A)W&]*4O-NI8MV9_C*LQZ,A^'<_::\FN"YCFXHL:=KO:]CMFRVMW\
MY6O25C?\UL#_`)Q?\XO4N^U_Z/<WTOYK[)]#9O\`YO\`X3Z:<#5^3%FQF8@!
MTF)'^Z')Z%]3NJ4=?=USK68S+R&[BSTP1N>YOH[[-S6-8VNGVUU5KH.H],&6
MX6UNV7-$2>"!Q,?NJ^DHL^''G@<>6/%$_LZQ7XXC'\O4V?JY%?1LBRUK\V[U
M&M[222!^;N=]%JN]0Q7Y6/Z3'!IW`R>-/@K22AQ\A@ACR8P#6;^<D9&4Y_X;
M(9$D'LAQ*748U=+B"YC8)'"Y3#^HMV/]:CUAUU1PA?9D5T`.WASP7-'[GLN>
M]R[%)681$(B$=H@1'E%CG",R#(7PGB'FY/UHZ/?UKH]O3\>QE5ECF.#W@EOM
M<'_F_!#Z9]7S1]5V]!S7BR:;*;;*Q`BPO.ZO?^<SU%M)(VK@CQ&74CA_P7A.
MG_43K^/CY/3K>JM9TV[<XTT`@VOV[&>LYS=U-3_9]H92_P#2_P`VM3HOU1NQ
M/JSF=#SKV/=F.L)MI!AN]K&M]MG[CZ]RZ=)&RLC@A&J!T!CO^B7A.G_4?ZRT
MXEO3+NK-IZ;9N+J<<'<]Q'=]C=]-+W?S]=;_`-(MOZG?5[+Z!A9&-E6UW.NN
M]5KJ@X`#8RO:=_\`Q:Z!)*U0PPB01=@4+/1__]+T_*_HUG\WQ_AOYO\`ZY_)
M2Q/Z.S^;X_P/\W_87RVDDM_2^C]5)+Y5227/U4DOE5))3]5)+Y5224_522^5
M4DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+Y5224__V?_M$?Q0
M:&]T;W-H;W`@,RXP`#A"24T$)0``````$``````````````````````X0DE-
M`^T``````!``2`````$``0!(`````0`!.$))300F```````.````````````
M`#^````X0DE-!`T```````0```!X.$))3009```````$````'CA"24T#\P``
M````"0```````````0`X0DE-!`H```````$``#A"24TG$```````"@`!````
M``````(X0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F``$`H9F:
M``8```````$`,@````$`6@````8```````$`-0````$`+0````8```````$X
M0DE-`_@``````'```/____________________________\#Z`````#_____
M________________________`^@`````____________________________
M_P/H`````/____________________________\#Z```.$))300````````"
M``$X0DE-!`(```````0`````.$))300(```````0`````0```D````)`````
M`#A"24T$'@``````!``````X0DE-!!H``````TD````&```````````````T
M````I0````H`50!N`'0`:0!T`&P`90!D`"T`,0````$`````````````````
M`````````0``````````````I0```#0``````````````````````0``````
M```````````````````0`````0```````&YU;&P````"````!F)O=6YD<T]B
M:F,````!````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L
M;VYG``````````!"=&]M;&]N9P```#0`````4F=H=&QO;F<```"E````!G-L
M:6-E<U9L3',````!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)
M1&QO;F<`````````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````
M#$53;&EC94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````
M"D53;&EC951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C
M=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O
M;6QO;F<````T`````%)G:'1L;VYG````I0````-U<FQ415A4`````0``````
M`&YU;&Q415A4`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%
M6%0````!```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%
M6%0````!```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX`
M```'9&5F875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG
M;@````=D969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O
M;&]R5'EP90````!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/
M=71S971L;VYG``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H
M=$]U='-E=&QO;F<``````#A"24T$*```````#`````$_\````````#A"24T$
M%```````!`````(X0DE-!`P`````#"<````!````H````#(```'@``!=P```
M#`L`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!
M9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1
M#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.
M$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#/_``!$(`#(`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!
M`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$
M!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21
MH;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7R
MLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'
MU^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!
M4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3
M=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,
M`P$``A$#$0`_`/54DE5S;,NH"RC86@>YK@2XG\W;M*9DR#'`S()$=^'4J`MM
M)*I1F/RL0VT,'J@[36\P`X'W`N:J3NM93;C2:&>H';(W'F=O@J^7G^7QQA*4
MCPY1<)",I1E?33]+^JN$";\'1S<[#P,9^5FW,Q\>L2^RPAH'_F7[K5CMS^O=
M9UZ96.EX!^CG9;"Z^P?OXN`XL]%FG\[F_P#L(BW],Q&Y!ZUU-AOR:8^S5/>;
M*JCH&NQ:7-975<]WTKMGJ_\`"(_V_.9CNR7TML)&VG&9(>ZP_P`VSU'>S9^_
M;^8I?O$/<CC'$9S'%P\/R1[SXOE6&,J))J([;EH8#NI8WUH=TTY]O4,48?VC
M)]=M4UVNL].CTWXU6/L]9C;?T+OW%T2SNC=+=@56VY+Q=U#,?ZV;>)ASXVLJ
MKW>[[/CU_H<=G[BT5,B`-:]=5))*IF]1HPX#Y<]VH8WF/WG?NIF7+#%`SR2$
M(#>17@$Z!MI+.Q>M8]]@K<TU.<8:3!$_NRK.=DV8U'J5U^J[<!M$]_ZLJ*'.
M8)XI9H3$X0^8Q!L?X/S*X2#1#820L:UUV/7:]NQSQ);X?>BJ>,A*(D-I`2'E
M)"DEF?6'JF3TKI=F;BXYR[6.8!2-TD.<&D_HVO=[5/H/4<CJ?2<?.R:#BW7`
ME]!F6PYS/\(UC_S=WT45O$.+AZU;H)*OU#,9@8&3FO:7LQJGW.8V)(8TV%K9
M_JJG]7>OT=?P79M%3Z&,M=5LLB9:&NW>PN_?23Q"Q&]3T=1))))+_]#U5`S!
M.,_2>#X\'^I=_P">D=97U@ZQ^SL>NBBK[7U'.<:<+$F/4?'O?8?S,:AGZ3(M
M_,8FY(\<)1_>!C]JK`U/1HNS,_"Q\EG3L8Y.=?<VK'K,BMCG-<?M.6[;7Z6+
M5M]_Z/\`2?S-:@\.'4`'F7BUN\C0%VYN\M'[NY:`Z=U"I[+\=U5=FP"QC9VS
M^<WW3ZK=WT'_`*-ZS;/6^VG=M]?U=8^COW?]3N7.<[[F/!@PY,<HG%F)XOFA
MDC*7&."7^$RQUD9`[C;LZW6]::*QJ7VC3Q@.\G?]2K."V*)(@EQ(TC_T5C_^
M>U4_9^??>VW+LK(:"&M@N`G]UOL]W\M:3&,K8&,$-;H`M;EH9)\SDYB4#CA(
M"$(S_G#P_I<*TD<(&[)<5U'ZT?6"GZWW]&P*ZLENT-QJ'PSWNI9?ZEUWTO2I
M_26O8WWO_FV+M5Y^?_RL#_7_`+1K0'7R:V<D>W1(XLD8FNQ;/0_K+]8:/K.>
M@]>-5CK):U]8#0QVSUZG5N8&^I3;7_I&>KO_`+:V^K!U/4:[[&;ZR&D`\';]
M)BYCJFO^,_%CL:9_[;>NXOR\%]WV&WWO>=I86F`2-S?<53^)889<,8G)'%+B
MB<<I?*<H^6/#^EQ+N5E*Y@W+AD8Z[\*$T].ZHYMP<=S![F@[7>7J?G>W^2C=
M3R+<;%]2H@.W`:ZZ%974,7]G7UW8[R`9+`>1'+9_.8Y7^LNW=/#N-SF&/BJ(
MSR&'G1*`P\UBCQ9)XMLGI_5Y(EL5K'6XGNYWUDZKU7"^K(ZI@O8V^MU;KBYN
MX%CCZ+H;_6L8]5<WZU957U(IZU46#-O#*P2V6^KO]*YVS_K=KEL.PF]0^KS\
M%W&3CNKD]BYI:UW]ER\KKRKL[H^!]7AN]8YSB6]AZ@%+6_V+7WK6Y8F6#$3J
M3"!)/]UI<S.4)FCI.)C$?U[_`$7N\KKO6\7ZCU=8L>S]H6BM\[!M#;'^QOI_
M\2Y7NE=?O/U/;UW.BRYE%EKPT;`XL<]K&-^ELW[6L5?Z^5,I^J-E-8AE1I8T
M>`:]C6K-I_\`R5G_`,+N_P#/SE+T^JC*4<DA9/#BXO\`"'5H4]<^N/5.A]3S
MKJZ<GICJKJ;6-BI]8+'>I=C:'U:\9K_?ZUF^S_!K5_Q=Y%6)]5<O)N,547W6
M/(U.UM=3G1]R!]7H/^+CJ,<BK,G_`#7HO^+_`#*,#ZI9F;D$BG'OMLL(U,-9
M4?;_`"DCU\UF.^/'(R)N$I7+5SF?6CZ\=7HR>J=+J91T_%W%S-K"0UH]1S9O
M]]UK*O=;Z?I_\&NJ^J'U@LZ_THY-[&UY%-AIN#)VD@-L;8S=N<UKZ[&KF_VC
M]:OK3@YF;5:WI/1J66>Q@W6V[&E[J_4/N_X.U[/0K_,_3^]7/\5NO2,P\?K7
M_HJE([)Q2E[H'%*491)N6QK]R/Z+_]'U'(OIQL>S)O<&4TL=98\\!K1O>[^R
MT+"^K.+=G6V?6?J#"W*SV[<.IW^`PYW45#_A<C^D9#D7ZVY_3L;IXQNJ[Z^G
M=1+\7(R63^BW,<ZMQVA_TW,V?10#]=ND61C]&JOZO>T0*L2IVQO9GJWV"NBF
MO^6BQRE'BU(]/3Q>C7)/R?M74[!@%MK6Y&U^69-#';OYMA']+R?^`I]E?^'M
M5MO2NN=:._K]HP\%W'2<1Y]P/YN?G-V67<[;*,;TJ/\`C%HGH>)#&M<^ME8V
MU5U[6,8T?1956QFVMJH\_P`L<T<?##W98Y<<8F7MPO\`K_IR_N19(2)O]`'K
M^E_Z"WJF%C`USB]W+G'N?A^:IH=%)I9L-C[=9W6&3\.`B*Y$D@&0X2=QO2E+
MS;J6+=F?XRK,>C(?AW/VFO)K@N8YN*+&G:[VO8[9LMK=_.5KTE8W_-;`_P"<
M7_.+U+OM?^CW-]+^:^R?0V;_`.;_`.$^FG`U?DQ9L9F(`=)B1_NAR>A?4[JE
M'7W=<ZUF,R\ANXL],$;GN;Z.^S<UC6-KI]M=5:Z#J/3!EN%M;MES1$G@@<3'
M[JOI*+/AQYX''ECQ1/[.L5^.(Q_+U-GZN17T;(LM:_-N]1K>TDD@?F[G?1:K
MO4,5^5C^DQP:=P,GC3X*TDH<?(8(8\F,`UF_G)&1E.?^&R&1)![(<2EU&-72
MX@N8V"1PN4P_J+=C_6H]8==4<(7V9%=`#MX<\%S1^Y[+GO<NQ25F$1"(A':(
M$1Y18YPC,@R%\)XAYN3]:.CW]:Z/;T_'L9598YC@]X);[7!_YOP0^F?5\T?5
M=O0<UXLFFRFVRL0(L+SNKW_G,]1;22-JX(\1EU(X?\%X3I_U$Z_CX^3TZWJK
M6=-NW.--`(-K]NQGK.<W=34_V?:&4O\`TO\`-K4Z+]4;L3ZLYG0\Z]CW9CK"
M;:08;O:QK?;9^X^O<NG21LK(X(1J@=`8[_HEX3I_U'^LM.);TR[JS:>FV;BZ
MG'!W/<1W?8W?32]W\_76_P#2+;^IWU>R^@861C95M=SKKO5:ZH.``V,KVG?_
M`,6N@22M4,,(D$78%"ST?__2]/ROZ-9_-\?X;^;_`.N?R4L3^CL_F^/\#_-_
MV%\MI)+?TOH_522^54DES]5)+Y5224_522^54DE/U4DOE5))3]5)+Y5224_5
M22^54DE/U4DOE5))3]5)+Y5224_522^54DE/_]D`.$))300A``````!3````
M`0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$@!!`&0`
M;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P````$`.$))300&````
M```'``@````!`0#_X1?Y:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\
M/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z
M:V,Y9"<_/@H\>#IX;7!M971A('AM;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X
M.GAM<'1K/2=835`@=&]O;&MI="`S+C`M,C@L(&9R86UE=V]R:R`Q+C8G/@H\
M<F1F.E)$1B!X;6QN<SIR9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O
M,C(M<F1F+7-Y;G1A>"UN<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N
M8V]M+VE8+S$N,"\G/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U
M=6ED.C)E,C!D-C$Q+3,S9F,M,3%D82TX930T+6%C8C$Y,&5A,V8W92<*("!X
M;6QN<SIE>&EF/2=H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R<^"B`@
M/&5X:68Z0V]L;W)3<&%C93XQ/"]E>&EF.D-O;&]R4W!A8V4^"B`@/&5X:68Z
M4&EX96Q81&EM96YS:6]N/C$V-3PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B`@
M/&5X:68Z4&EX96Q91&EM96YS:6]N/C4R/"]E>&EF.E!I>&5L641I;65N<VEO
M;CX*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2=U=6ED.C)E,C!D-C$Q+3,S9F,M,3%D82TX930T+6%C8C$Y,&5A
M,V8W92<*("!X;6QN<SIP9&8])VAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N
M,R\G/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70])W5U:60Z,F4R,&0V,3$M,S-F8RTQ,61A+3AE-#0M86-B,3DP
M96$S9C=E)PH@('AM;&YS.G!H;W1O<VAO<#TG:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W`O,2XP+R<^"B`@/'!H;W1O<VAO<#I(:7-T;W)Y/CPO<&AO
M=&]S:&]P.DAI<W1O<GD^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HR93(P9#8Q,2TS,V9C+3$Q9&$M
M.&4T-"UA8V(Q.3!E83-F-V4G"B`@>&UL;G,Z=&EF9CTG:'1T<#HO+VYS+F%D
M;V)E+F-O;2]T:69F+S$N,"\G/@H@(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I
M9F8Z3W)I96YT871I;VX^"B`@/'1I9F8Z6%)E<V]L=71I;VX^-S(O,3PO=&EF
M9CI84F5S;VQU=&EO;CX*("`\=&EF9CI94F5S;VQU=&EO;CXW,B\Q/"]T:69F
M.EE297-O;'5T:6]N/@H@(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z
M4F5S;VQU=&EO;E5N:70^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HR93(P9#8Q,2TS,V9C+3$Q9&$M
M.&4T-"UA8V(Q.3!E83-F-V4G"B`@>&UL;G,Z>&%P/2=H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O)SX*("`\>&%P.D-R96%T941A=&4^,C`P-2TQ,"TP
M,U0P-CHU-3HQ-2TP-3HP,#PO>&%P.D-R96%T941A=&4^"B`@/'AA<#I-;V1I
M9GE$871E/C(P,#4M,3`M,#-4,#8Z-34Z,34M,#4Z,#`\+WAA<#I-;V1I9GE$
M871E/@H@(#QX87`Z365T861A=&%$871E/C(P,#4M,3`M,#-4,#8Z-34Z,34M
M,#4Z,#`\+WAA<#I-971A9&%T841A=&4^"B`@/'AA<#I#<F5A=&]R5&]O;#Y!
M9&]B92!0:&]T;W-H;W`@0U,@5VEN9&]W<SPO>&%P.D-R96%T;W)4;V]L/@H@
M/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70])W5U:60Z,F4R,&0V,3$M,S-F8RTQ,61A+3AE-#0M86-B,3DP96$S9C=E
M)PH@('AM;&YS.GAA<$U-/2=H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O
M;6TO)SX*("`\>&%P34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H
M;W`Z,F4R,&0V,3`M,S-F8RTQ,61A+3AE-#0M86-B,3DP96$S9C=E/"]X87!-
M33I$;V-U;65N=$E$/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z,F4R,&0V,3$M,S-F8RTQ,61A+3AE
M-#0M86-B,3DP96$S9C=E)PH@('AM;&YS.F1C/2=H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R<^"B`@/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D
M8SIF;W)M870^"B`\+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^_^(,6$E#0U]04D]&24Q%
M``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`,0``86-S<$U3
M1E0`````245#('-21T(``````````````````/;6``$`````TRU(4"`@````
M```````````````````````````````````````````````````````````1
M8W!R=````5`````S9&5S8P```80```!L=W1P=````?`````48FMP=````@0`
M```4<EA96@```A@````49UA96@```BP````48EA96@```D`````49&UN9```
M`E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P```]0````D;'5M
M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E120P``!#P```@,
M9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y<FEG:'0@*&,I
M(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`````````$G-2
M1T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V,3DV-BTR+C$`
M````````````````````````````````````````````````````````````
M`````%A96B````````#S40`!`````1;,6%E:(`````````````````````!8
M65H@````````;Z(``#CU```#D%A96B````````!BF0``MX4``!C:6%E:(```
M`````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO+W=W=RYI96,N
M8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````````````
M````````````````````````````````````````````````9&5S8P``````
M```N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO
M=7(@<W!A8V4@+2!S4D="`````````````````````````````&1E<V,`````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@
M245#-C$Y-C8M,BXQ``````````````````````````````````!V:65W````
M```3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@``````!,"58`4```
M`%<?YVUE87,``````````0````````````````````````*/`````G-I9R``
M````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`*``M`#(`-P`[
M`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`
MK@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!'P$E
M`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y`<$!
MR0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"A`*.
M`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R`WX#
MB@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$<01^!(P$F@2H
M!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&
M!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'=`>&
M!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)
M3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY
M"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-
M=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/
M#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02
MA!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56
M%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48
MBABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:
M'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?
ME!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F
M(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHG
MJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTKT2P%
M+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0P
MVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"
M-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[
M+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F
M0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&
MJT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ
M30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'4Q-3
M7U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'
M6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA
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MB?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2
MXY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<
MG(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF
M&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``
ML'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZ
MM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+
MQ<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0
MNM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%
MW(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH
M,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T
M],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X`
M#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!
M`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#_\``$0@`-`"E`P$1``(1`0,1`?_=``0`%?_$`:(````&
M`@,!``````````````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$
M`P<""`$)``H+$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C
M%0E10A9A)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H
M5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&
MAXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CI
MZO3U]O?X^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q
M"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&
M=,+2XO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&
MUN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*
MFJJZRMKJ^O_:``P#`0`"$0,1`#\`W^/?NO=>]^Z]U[W[KW7O?NO=-^6R^*P&
M+R&;SN3Q^%PN(HZG(Y7+Y:MIL=B\9CZ.)IZNOR&0K)(:2BHZ6!&>261U1$!+
M$`>]@%B%458]-330VT,MQ<2K'`BEF9B%55&26)H``,DDT'594WS:[=^469K]
MG_R[.NL'O3:-!65.+W'\S.YH<[A_C9A:RE<P5]'U9A<;]CO/Y!9^BD#+KQCT
M&WXYE7R9)T?VO%I%;J'O9"&/!%RQ^WR4?S_,=1B_.^\\T3R67MUMJ36BL5?<
M;D,MFI!HRPJ*27+BA^'3&"%JY5@>@*[BH_F;\9>]?A!;YO;X^0&\?D%\E,/U
MCO\`Z8SW5?4>SNL\KU-%MO.;G[1W=M'`[2VS_>[:HZZP>+2H%3+F<C(&FB$T
MCZBLK\7TEQ%>'Z0(B1U!!).JM`"3Z_LZ#^\ISMROOG(@_KQ-N-]N.Z+#-;O!
M;Q0M;Z&>>2-$76G@J`:ZV;*DM35JNZ]E'4Y]>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__T-_CW[KW
M02=L[I[`V=C*7.;.PVV,OC*1:E]PKGJK/0UJ`R4D6-BQ$&"QF4FGDJI971R\
M>F,Z2;+J(Q\^\#SY[M>W&R6/-/MWR[LFX;%;+(VX"]DOEF%6B6V2T2QM[EW:
M5V='+QE4/ALU$ULIKM5K8WDC07<TB2FFC2%IYUU%B*4QYYSYTZ;>NNXU[0V!
MEMS[7VY.^Z\(:K'Y'8V1R$..J8-P4T0DCQDF3J8!%!35EQXZB2);<AD5E901
M^SGWD5]]/:/F#GGD/DR5^?\`:S+;W&R7%PEM(FX1+J6V:ZDC"I%-CP[B2):=
MRR1J\;HKNX;/^[+^*VNK@?2O0B0"HT'ST@Y(\P#]AR.B\;M^:&<V-G\CM?='
M3[XW-XIH5KJ3^^U)5+']Q3Q5<#I44F"GIYHY::='4JQX/];CWAM[@_WF?-'M
M9S?O'(?/?W<7L>:K!D$\/[[BE"^)&DL962*P>-U>.1'!5B*-0T((`AM.38+Z
MWCNK7=]4#<#X9'`T."U>(Z8.S_C?MWY75>-[!^6D'8F,Z:V#CJ7<M)\=9^Q\
M#5=$[TGIJ=LNN[.S=L;6V[B]Q[TJ\(T$;PXS,Y.KQ6H_\`B=8;/+VS]Y^>+[
MD/F;G[W@]KH>2MBL[-;R.5]R@W%Y;/P'GFE<01I],8D"_I,ID<M0`,M.HHYK
M]O-FYDWC;DN]ZN[^PC:GT6(K5I0PTO*H4/,01@/(8Q_`0344.M.[,GGH%GVK
MLG9G7W26RJ)S4OE6RF$K,/L7#4<RT^2PV-Q^$I=J4>.AIZ/3%2PU$@@CC9>`
M%)@OV1^\][J?>&YS2ZY*]O=ML?:R.Z_6DOY;X;G+9DLL=W`%MEL"9G4@1+<S
MLA5PQI1R.=RV79^6=L*SW.@Q18$:HL,8096@-55%_HJ*4H/+I*=&]1[B[,[U
MSOS5[GP];B,_+MRNZV^,G6N:A,5=T]TI6UD5;F=TY_'OZ<=VWW=D*6&NRR$&
MHQ&%@H,4[":*M5L]II%CB%I$016KG^)O0?T5\O4U/IU$FP;3<[KOD_.^]0M'
M.8S#90-@V]L35I'7\-Q<FC..,<82(G4''1[O:/H?=>]^Z]TG=U[KV_LC`9#<
MVY\E#BL+C(A)55<P=N798X8((8U>:HJ:B5@D<:*SNQ``]@[G_G_E'VOY2WCG
MCGK>HK#EJQC#2RO4\2%1$107DED8A(XT5G=B`H)Z46MK<7L\=M;1EIF.!_E/
MH!YD]%4@^<G4DN2%)+BMZ4U"T@3^*RXO'/"BEK>>2C@RTU>(0.3IC:2W]F_'
MO`*U_O3_`+O,^^+MLVP<S0[47T_5M;6QC`K36T27;SZ//MC:2G^AUQT*6Y(W
M81:Q+"7I\.IJ_94K2OYT^?1N<+FL3N/$X_.X.OILIB,I31UF/KZ2024]33RB
MZNC<$$&X92`R,"K`$$>^B7+/,NP<Y;!M/-/*^ZPWW+U]`LT$\1U))&W`@X((
MR&5@&1@5<*P(`3FAEMY9()T*RJ:$'B#T`?3/R#3MW=6[MLKM*;;YVK$\IK9,
MN,@*[1E)L;98!C:+P7\.N^M_K;_'WB3]VK[W\?WB.??<+DA/;]]H.PQEO&-X
M+GQZ7+6]/#^E@\/X=7QOFJ^6HGN\;`=IM;2Y^J\3Q3PTTIBO'4:_RZ,A[S2Z
M#O7O?NO=5!=3?S7(>T?YD78'\O<=$5^#EV+DNP<>>VGW['74F4_N'@Z;-&9=
MH#9U&]*,I]QXP/XG)X;!KO>P,Y=M,=@E[XI-:8T^OSK_`)/7J&]H]VEW7W+W
M#V[&QZ#`TH\?QJU\)=7]EX0I6G^_#2H.:]6^^RSJ9.JZ_DQ_,Y^//Q2^2'4/
MQ<[*PO:-?V-W7%LN7:-;M+;6#RFU:9=][XKNO\*,YDZ_=6(KJ(Q9N@=ZCQ4D
M_CI[.NMCH]KK?;Y[F"6XC*^&E:UK7`KZ'J-N:/=+ESE+F;9^5-S@NFW*^$1C
M,:QE!XLK1+J+2(P[E)-%;'"IQU8I[0]23U[W[KW7O?NO=?_1W^/?NO=(#M.(
MR]>[L4:?1BI)V+O#&BI32Q5$CO)49W;,$:(D1)9Z^E0`7+VX,1>_4!N/9WW`
M0::+M[2$L450L3+(Q+27^V1J`J$EGO[5`!5I0`05^UFFX6G^GI^W'DKG]BM]
MG57F%^26U_BK0?(+L;.83<F\J;R[$QNT-@=>8V/<6Z>PNQ]W9E\!LO9>UZ'!
MYK=M&V4W-G\U'3>=J^H@I]9>:0$%/?.C^[HN0OO[]Y+EO;[J']W7%K97FF.2
M!HJI(P:13;[AND+4-V0Q2_N34]\@;4JKO=3?[;ECE/;M\O+::5UD\*.-%9I)
M99#IBB4%$-78`"J`#R!P"#':N8[%W%N6FS_;VU,7L3M+.;-V-EM_[(PN47-X
MK:&Y\AL_#U60VU1YE'D3*IAFD$#U"L4ED1F7TD#W@7_>(+&OWOO=98FU1#]W
M4/J/W99Y_/H;>W<VXW/)FPW&[VBP;H\1:6-3J$;EV)0-4UT\"02":TZM&^1V
M1?'?&7.M')XGK,'M/'`@D%TK<CA8IXA;D^6F+J1^03[Z\_?/WF79?N/\TO!/
MX<USM>TVX-:$K-<V2R*/]-'K!'FM:XZ"?+L8DYD@!%0'D/[`U/Y],OQ:Q>/G
MVQE:=HJ"LH8J+:4!A23$UD'W5+!/7#S)C=][Q@6:*H9)-,E/C7#V;Q$^F,C_
M`+ONRMK7D_?C8R0-;Q6>UP_I26KT<02NX;Z7?MX57JX++);[:]6J8#4I%;FT
M"6:)94J"[FA!_B%/BBCKD8RXQQ]3>^^A?06ZI!_FW?S2NS?Y=6^/CA@]D=>[
M"WKM_MR+>-=O&KW8FY9<MA\=M/,[+HY3MNGP68Q4%15S8_<50P2<.&FCC`L"
MUSC:]M2_2X9G(9*4H?6OR/IU!/O#[L[E[:W_`"S;V>WP36]Z)3(7#EE$;1CL
MTR(*D.>-<T_,C?>?\\?YQ_&[N7K;<7>WPAQW4/Q:[2K9,AL[&;R;,#N3-]?4
M5;0Q9;.MFZ#<<VW<)O?&8S)05LV!K<1%+")DA=R'6J]K(=GL[B&40W1:Y3C2
MFD'[*</G7_-T`^8/??GSEC?=JGW[D=+3E.\:L:R!_J6B!`+:@^E9`&!,;1`@
MD*<$.;P/F=43[EZ7VCN/;LK9':]3N#"YVIK*4.T$N*RF%KCA<C(+`BDEEK8[
M,P`#RI?DCWRH_O4MKYDO/8/ENYVJ&5]EM.8X7O=%:(C6]S%#)(!_H8F<)4X$
MDD8XD=9P<A7-K+?F57!$MO6,^H)5L?:N?LKTD>IMN]$]T=,4'6U)'@=O=C4F
M-455;/CJ1-U1YVG<R2Y^AJ':FJL]CZHW,D23%5A;QN$TJ1$?W?.3ONH?>:^[
M/M/LKM]OM&S^\EO9`2S26T0W1;Z-BSWT$A:*6^MY<EXDG(2%O!D6+3&09[K<
M;YLV\ON+F23;RV`"=&D_A(R%(\C3CD5ST<'J+K"CZCV=#L^@S>4SM-%75>0%
M5E!3QM%+7>-ZB"C@IHU6FHC.C2",M(P>1B6-_?1S[O'L9MGW>/;BU]N=HYFO
MMTL8[J6<27(C70TVDR1PI&H$<)=6D",TC!Y)"9#JP$=VW-]VO&NY(51BH%%K
MY<"2>)IBN,`8Z!KH#OG/]K;TWSMS*X#;^(IMLP22TM3B5K14U17,3X\"J-34
M2QD&.(-Z0/5_A[QM^Z-]Z_FOW\]R_=+DW?\`E/:-OLMDB9HI+19EDE(NF@I*
M9)9%(T@-VA>ZIX&@-]^V.#:[.RN(IY':0Y#4H.VN*`=5W?R[?YH?<ORB^8WR
M7^(7?77'6O7^Z.C:;=[82HV.^Z(ZG.U>P>Q4V-N6.NAW'E\FK1M#DJ*J@\(0
MZ&<FXM;HY?;=';VMO=0LQ1Z<2#Q%1P`ZQ?\`;CW5W?FKG3F?DW?K"V@O+`2:
M?##J6,,HBDKK=ZBK`B@&`3D''OBW_-$[E^3G\S7O?X>[=ZWZUCZ)Z/J>T5RG
M8]))NB;>U52=?9?&[(HYM;98[<#YC?>0T@"E`-$C:?6-?OUSMT=O80W3.?%>
ME!44R*\*5X5\^/7N5/=7=^:O<_?^3;7;[;]Q6!GU2@/XA$+"+XM>BIE(_`*J
M33(J6CI#^:#VGV7_`#:NS_@7D^K.JL9L#966[1H*'?\`BX=Q#L&NCV3MRER]
M#)72U&6EPIDKII2D^BG4%`--CS[W+MZ)MJ7@=M1`Q7&:>5/GZ]-;%[I;GN?N
M[NG(,FV6JV,+S`2JKB4^&K$58N5R5SV#!\J98_YJ/\V_M_XD]^]4_%#XK]5;
M2[2[LWYC-O9G*#=U-G\U3PU&\\]5;?V3LG;VW=N9C;E76[ES]50232335BPP
M02P@1N9&>*^V[9%=0RW-S(5A6O"@X<34@X_V<])/=OWAWKD[F#9^4>4MIANM
M]N51CX@=Q61RD<:HCQDNQ%22V`R@*:U%'7S;[S[N[T_F@?`K)?(WX\Y_XU]R
M;+S7QOV;O'9.2R%+FMO9NIC^0%9G*?>6P<Y1SU4&3VCEXLQXD'FJ6I:NGGIV
MGF:(N3FRAAAVV]$$X>(ZR#Y_",'Y_L\C0=0+S[OV^;][L>WTG,G+LFV[U"UE
M')&3J1B+MV$D3`FJ,'I@L%8,NMBI/6RE_-8_FDX#^7+LK9%#@]F4W9G=_;,N
M7786S\ADIL9@,9B<$:&'*;KW3-0QS9:HH8Z_)T]-24-*L<U?.[@30K$[>P[M
MNWF^=M4FF)>)\_L'^H^6.LH_=GW3A]MMOLA;6'U6]W9;PHR2$55IJ=R,D5("
MJ"I;N[ETGJJ?;W\]3YS?'[M_K#;O\PCX@[?ZMZR[2DH:RERF'VSOC8N[\3M>
MNKJ6AJ]U8JGW1NC=F-W)#M@UT<M?C)%HJ]8R%9HG=%<T;9K.>*1K"X+2+\P<
M_D!2OKU$%K[^<^<N[UM5M[C\HQ6FU7="&6.:%U0D`N/$DD#Z*@LE`W`%EJ.M
MKO[JF^U^]^XA^S^W^Z^Z\B^#[;Q^;[CRWT>'Q>K5>VGGV&?EY]9=:UT:]0T4
MK7RIZ]?_TM_CW[KW1=?E7\B^LOBST=O+M[M:JJS@,93)AL3MW#QFJW5OW=^>
MUX_;&P-EXR,-497=FZLDZT])#&IT7:9],44CJS<[5%O=K=[3<`FVN(GC>AI1
M'4JQKY$`X/$&E,]$/,O,UARAM-QOFX,=$5`B+EY9#\$4:^;N<>@%6:BJ2"H8
M79O?V.JM@]X;3ZCR6'S.X=H8/*[EV#O?=F,W'NS"ODL?15S;1WC2^:DHX]P[
M7J%$/W&,J9D\L0:R-JC]\E.?/8?[S7L1[XQ>[?W?>5%YAM%@DMKAYMS-Q-N%
MDWAA(;ZVN?I)(Y8_#72UG-,A,<;]O=&9,V7>]KYBY<LH^8+=[*YD1)?!9%K!
M(14@,FI25)(-0#QX'HL/>.<W)N7LS<F9WAMI]G[AJTQ2Y';\DK3M0?;X:AIH
M&\KJC,M52Q),..`_U/U]\M_O5<U<Z\Z^^W.G,GN'R2W+O-\XM!/8,Q<P>'96
M\<9U,`2)8D248P'`!(R9#V."VMMLMX;2Y\6W&JC>M6)/[#C\NC<;CH/D9WIC
M]I[:R?5M/M[86,EQE;54M9N"+$#-FEI%AI:C(Y1FJ<G'2(CF18Z6B9KM>[,$
M*]%^<MJ^^9]ZC:?;SDG>_8F'9_:6R:VFFCEOUM/K?"A"1/<7+&2Y$(5BZQVU
MFS#42=;K&R!*WDY>V1[NYBW,R7[5`(75IJ:D`8%?F6_RU/5L':";,V_!BVJJ
MFLK)66JR$]375&1`JV@ABDIZ.IJHXJDX^G\6F$.H:UR0"2/?5/VD]NH_;3E"
MUV-[Z:YW.0B6XDDGDN*2E$5HX99560V\>G3"'4-2K$!F(Z!%_=F\G,ND*@P`
M`!BO$@8J?/I:^Y/Z1=:@O_"GG_F9WP=_[57;O_O1]5^Q5RY_9WGVK_EZPQ^]
M9_R5.0_])<_\>@Z%3_A4'%$>A_B+,40S)V+OZ*-R!K6*78F.>9%/U".\*%A]
M"5'M/R__`&MU_I?\_1]]Z4#]Q<FM3N%S)_QV+_,.M@#I/<VQ\-\3OC]_I$S6
MWJ'$Y?H+JR&JAW/64209:-^O=N_>0_;5KELB6$HUHJN?4+CGW#GNOSE[4\J;
M+N5M[M\Q;-9<M7RS1-%N,L*QW2<)(EAF-;C#`-&B.>X8R.LF^1H+^XY;Y7>R
MBD>X6PMC5020?!3)(X?:>BX]Y?&##[;V_4=N=0YB>EQ./IH-R2X<5DS_`&N-
MD$=3'E]KY@.*V)*:*19A%*[,(P2D@(5#Q\^]1]Q3EWDKE"\^\-]W/F.:WV&S
MACW%K,3.?#MVTR+=[;=ZA,JQJRS"*5F?1J>.>JI$9>V3F::YG7:=WA!E8E-5
M.)X:77AGA4>?$>?1GOBOVCF.S^MC/N.8U>X-M923`5^090LF3ACI:6KH*^HT
M@(U7)35/CE8`:WC+GEC[SH^X1[\<Q^^WLF;WG.X-QS=LM\UA/<$4:Y18HI8)
MWI@RM')X<K4&MXS(<N>@US1M<.V;EIMQ2WD74!_#D@@?*HJ/MIY=%M^%O_,U
M>W?^H.;_`-ZBK]X6_P!V=_T_O[PW_/.__=Q;H1<Y?\DO:?M_Y\ZH<^4NZ\7_
M`"ZOY^%/\@,J%PW6G=766:WWF'D;PT-8VZ.L-R[1S,,LBF-2\_:FQ:.LD4F_
MDJ%)N2+]UK9#?[+X"BLB-3^8/_'<=<[.;+V+VV^\"O,4S>'M=[:M*U<*=<$D
M9%?4W$>L_;]G0^_\)H>K\EEMG?*WY8;JIY)]Q=K]E8_8]#EJ@-Y*@8.&JWUO
M:>%VN7CR.X]\TZR-?F2BM]5]L[_(`UM;)A56M/MP/V4/0B^[!M4LUES=S;>5
M:YN[H1!CYZ`9)&'R<R)7YKT7[XD?]Q*?R"_\.7Y"_P#O#4/MZX_Y(,7V+_A7
MH.\H?^)-<P?\U;O_`(Y)UR^6"I4_\*5N@8JD":*'<?Q_:))1K2-H.OJZL@*!
MKA3%6`2+;Z2<CGWZV_Y(,WV-_A;K?-HU_>;V`.*@2VM/RCC(_GG[>I7\ZG_M
M\C_+W_Z@OC9_\$[N?W?:/^23??[?_CHZI[Y?]/L]NO\`2V7_`&FR]6^_S6?F
MI\2?AWCM@93M?H'8_P`D?D7NB"IBZ4Z_RVSMJ9S/TM+19*G/\;K=SYS`9_);
M2VU#N&2)8!1P3U==D!HIH6:.66$IVVUNKHN(IVC@'Q$$_P"`$5Q_JX#J:/=O
MG7D_DV/;I]WY<M]SYDE!%K$\4;,*&NHR.CM&FOAI!9F&!169=8C^<7O#^89V
M=B?C9VE\Z=D]<]18C>'^DJ;I7IS:%,\6Z=EXR*+8D^XZO?DE54YC)19+,0U>
M-$=-4Y!IX'@D$E)1N6C81[0MC&;B.T=F(TZF/`\>'`>O`?F>L4O?"\]QMTAY
M7W7GNRMK.&83_36\8H\:CP2YD!+L"P,>&D+`AJI&<'>V_P":1_\`E./_`)6?
M8+_T7_;?Y>N@/_+&_P"H7_GSK__3W\ZBH@I8)JJJFBIJ:FBDJ*BHJ)$A@IX(
M4:2::::1ECBBBC4LS,0%`))M[]UIF5%9W8!0*DG``'F>J8_C;CJK^8[\FI_G
M'OFGJ)OBM\>MS[BV1\%MC5Z%L1OK>.&JIL'OSY7Y>AE_9K9YLG22XW:9=":.
MGADJ%$=0HDD-)S]#!](M/J'%7/F!Y+_G_P`-#00QRU&WN/S,W/%Z&/*VWR/%
MML1IHED4TDO6'F=0TPU^&E=*NFIKH?97U-'5&OS0W9B\)\C<]MU8Z[.;RW4,
M+%M+8NWH(\CN[<IH]J8B7(5./QCSTT5)A,1`#+D,K72TF)QL"F2JJ84%_?SV
M?>P]DO<3WK^^=[P;?R-LRMMUC#M\U_N%PXM]MVVW7:K-GN+^]D_2MXU4%@I+
M2R4(BC=L=#Z'G#8^5.7MF3<YV?<KIG6VM85\2ZN7#MVPP@@L!^.1BL,8S)(@
MSU<;UO\`WMEVIAZO>,.'QN2JL7C6CP&"K3F*'"4ZT<2QTLFX6IZ3^/5SCU33
MQ004P-DB5U7S2]^^78(+7EWE^UMKI9X8[&W42K\$FF)!K2H!T-34E0#I(J`<
M=1S`]]+XDVX1+%.[$^&IU>&*GM+XUL/Q$`+7"@@:F7OLXZ4=>]^Z]UJ`?\*@
M$DD['^$D<,O@FDPG<20SZ0_@F?/]6K%-H-PXBD(:Q^MK>Q5RY_9WE?5?\O6%
M_P!ZX,=RY$"M1O#N<_[:#ID^;_Q$_G+_`#][/Z)^/_>W5/6$&P.JZNKI*?OS
MK6MH<9UIGZ+<RXBASW:>YHLON:IW'%FH,%B5\>%I<71R).TJQ4Q65775G=;5
M913S1.WB/^$\1QP,?/U/V]>YZY.]ZO<+=^7M@WW:[5=MLV-+J&@A</HU3OJ<
MM4!!V*B-75ICH1UL_=K?'3&;QZ>VIUUMR:"@R'6^'PV-V165P(A%-A,/3X1<
M;6O"KM#39&@I(U=T5O'+&C6(4J<)?OC?=M3[S/MG^XMOO(;7G;;K@W6WS2U\
M,R%2LMO*R@LL-PND,ZJQ22.*32P0JV<G*5]'RP;2W12;!(4B(''2@`4CRJ*<
M/0D=%&_N?\Q)=G_Z''P-8=JB-,7Y99]M^,8J.576@&XS6F5L2ND`*+R>(>/]
M'H]\O3[<?WD%Q[;_`/`W2\K7)Y#"BUUL^W4%HK@K!^\/&U&U%!1`YD$0$(_2
M_2Z'OU?*`O/WN)Q]5\7!_B]=%/B_E7/'/1YOC_U(W3NP8=O5E53UV=R-=/FL
M_5TH?[7^(5,4$"4E(TBI+)2T-+3)&KLJEV#/I75I'4_[H?W>6^[=[1VW)VXW
MT-US3>73WE_+%7POJ)$CC$418!FBACC1`[*I=M<FE`^D`G?MV_?%^;A%*P*N
ME0>-!4U/S)/Y<.@+^+W4W8.P.PNQ\SN_;LF'QF<II8\55/7XNK%6S9^IK`!'
M0UM3-%>F<-ZU7ZV^O'O%G[BOW?O=[VC]W_>?F7W#Y-DVW9-TA9;65I[642DW
MK2@!8)Y77].C=ZK@@<<='?,VZV%_8;=#:7`>1#W"C"G;3S`\_3JK_P#GX?R]
M>\/F/B/CQOOXW]>2=A]A]?93>6TMU8BFSNU]OU!V1N:CQ^8Q^1:JW5F,'13Q
M8?/X%HA&DS2WR)8(5#$=:-COX;1IDN'TQL`0:$Y'V`\<?LZPV^\/[<;]SM;<
MNWW+.VM<[E;O(CJ&C0^&X5E8F1T!"LK"@)-7X4J19#_*Y^,^>^)/P9Z+Z:WE
MB$P?85!A,GNGL?&+54-<]%O?>N<R.YLSCIZ[&U%9CZV;"KD8J`RP2RQ.M*"C
M,MC[+]QN!=7DTJFJ5H/L&/Y\>I/]J>5Y^3^0]AV2\A\/<%1GF4D$B21V<J2I
M*DH"$J"1VX)'55/QS^"GRMV1_/([D^6>Z.I:S%?'S<^<[FJ\%V(^Y]E5--7T
M^Z-IT>.P4BX&CW'4;H@%?6QL@$E$A2UW"BQ]F,]Y;-M$=LLH,P`Q0^H^5/+U
MZB;EOD+FVQ]]MYYNNMG9.7I9+@K-KB((=&"]HD,F2P&4'SITEOYNWP,^8]5\
MW^D/G[\+-AGL[<^U*78?\<V[0U>';*X3>O6F:K:O`92OPF9RN$&;VAN7`U<5
M!5K2SF:+[>0.$659!;:[VT%I-97;:5-:'Y$?X1GI)[Q^W_.LG/.P^X/(]E]3
M=0^%J0%:K)"U59E)4M&ZA5(6M-+5H"#T`W??P?\`YL'R=^97PT^67>W3VPY*
MS#;HZHKMV;-ZKSVU,=@NA-A;&[=HMQ+@L[6;DWO59?=^YZNDJZ_+UCT$N2BA
M65*>*5G7PHHM[S;;:TN[6*4T(:A-3J)%,4'#@/+_`"D.<Q\A^[?-7._)'.&^
M[-"726W,D<#1JMK%%<:]+EYBSO1GD;09!F@->Q3`_P`ZOX+_`#*['^67QS^9
M/Q1V!_I<JNKMO[-Q<NUJ:IPE1D=L[NZY[#S&_MMY:KV[GLGB(LYM?-S9A8JA
M:65Y8Y*5O(J+(CAC:+VUBMKBTN7TAB<^H(`/^K]G0C]\O;_G3=>;^6>=>4K#
MZN2T2)?#[3HDAF>9&*,1J1BP!TU^$ZJ`BI/?Y@_PW_G4?/\`QG3O:/;O1G7E
M/-A1N[%[:Z$ZOW-M'%576-!60;:J*[=6[\KN[?57%D<OOVHI$CCIJ?+5YHHL
M:!)'3-(0ZO;[O:;$S1QS&AH=1!->.!0>7V#CY]`GW*Y(][_<6#9-UW?8;?7'
MXJI:P/&IA!T$O(9)C4RD"@$KE0F5CKG<`_AV1_T8_P`)^QF_BW]Q/X=_#=<'
MW'\1_N_]M]CY/-]KYON?V[^3QZO[5N?85J/$K7&K_+UF=X4O[J\'PSXWT^G3
MBNK12G&E:XXT^?7_U-S7YL9?!YOIK<GQWE[-P_4F_/E9LWL_I+J?>.>J118N
MFWWF>M]R5E%2O4F2)_N:FDII?''$WW,MF$"O+H1E5H&$JS!"RQD,0,XKT#>=
MYK>;9KGEU]R2UOMVAFMH)'.E?%:%R`6\B0"!3N/X:M0'E%V)\8/@)\?>MMC]
MF]H]7]+;)ZLZ[VQM/&4FX=SXO%2U%/MO"TF.D_@N)D:'-[CKZR:G>4BEI):J
MIE=GT%V/OQCGO)I'CC9B6)X8%?7R`ZVNY<L<@[!MFW[GNMM9VUM;I&H=P&;0
MH!TK\<C,02=*EF))I4]%$QGS,^4/S>K!A/@/U56]5]*54G@ROS?^26T,CC,)
M4X]RZ2UG0'1N1DQFXNS,B\8U4F1S#T&%CE4K41-P&4FUM[3-[)JE_@7C_MCY
M?[-03T#XN=.:.>6\'D#:S:[(W'<KR,A2".-K;&C3'-59Z(&4I(JFAZ6&-_E_
M[LVP-RG`;[H<]N3?+TLW9_<'8V6S.YNY^X*JA"?9-OG=,6#HZ3&[7Q3H/X7M
M?#4]!MS$QJHBIGE4SMSB^]3[`?>D^\7+><L[1SWROR][4_4"0;?`UZ)+QT"J
MEQN<J68^HE4*-$8_1B`0#Q&19.IFY"VGE/D<37XAN[[F:X6D][<%9)WR3H5B
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MRY<;;N-O`MDLH82EP6\0QD:=*/PT&M:>7Y7>T\9AIX(6(+10Q1L1>Q*(JDB_
M-B1[)^IV4:55?0=9O?NK=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7_]7;5_FE_P"R'?[+./\`AP73_HE_OM@_[I_P
MW^\_]]O](_VF4_@W]PO[F?[^/^._PK[WR^/_`";[/R_<?MW]K]O^L\?_`!+^
MTIGA2GSK\Z4\Z\.HU]U/ZA?U9'^N%_R2?'7P].OQ/&HU/#\/NKIU:J]FC5KQ
MU6A\(O\`H'V_O[B_]&?]R?\`33Y8_P""_P"S=_W\_OGY[+]E_=W_`$]?[]'[
M^]OMOX9_E>K]'-O:^[_?6G]2NBGX:<//AW4]:XZC'D?_`('KZT?NOP/WKJ6G
MU_B5U4[=/U'Z&O\`AT=]>&>MDV#P>"'[;Q?;>*/[?P:/!X-`\7A\?[?B\=M.
MGBWT]D/V\>LEUTZ5TTTTQ3A3Y=9??NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
)Z]U[W[KW7__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
